Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma

References

• Parmar S, Platanias LC. Interferons: mechanisms of action and clinical applications. Curr OpinS Oncol 2003; 15:431-9; PMID:14624225; http://dx.doi.org/10.1097/00001622-200311000-00005
   PubMedGoogle Scholar
• Llobet D, Eritja N, Encinas M, Sorolla A, Yeramian A, Schoenenberger JA, Llombart-Cussac A, Marti RM, Matias-Guiu X, Dolcet X. Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anticancer Drugs 2008; 19:115-24; PMID:18176107; http://dx.doi.org/10.1097/CAD.0b013e3282f24031
   PubMed Web of Science ®Google Scholar
• Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003; 278:33714-23; PMID:12821677; http://dx.doi.org/10.1074/jbc.M302559200
   PubMed Web of Science ®Google Scholar
• Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67:227-64; PMID:9759489; http://dx.doi.org/10.1146/annurev.biochem.67.1.227
   PubMed Web of Science ®Google Scholar
• Uddin S, Platanias LC. Mechanisms of type-I interferon signal transduction. J Biochem Mol Biol 2004; 37:635-41; PMID:15607020; http://dx.doi.org/10.5483/BMBRep.2004.37.6.635
   PubMedGoogle Scholar
• Kaur S, Uddin S, Platanias LC. The PI3′ kinase pathway in interferon signaling. J Interferon Cytokine Res 2005; 25:780-7; PMID:16375606; http://dx.doi.org/10.1089/jir.2005.25.780
   PubMed Web of Science ®Google Scholar
• Lauta VM. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 2003; 97:2440-52; PMID:12733143; http://dx.doi.org/10.1002/cncr.11072
   PubMed Web of Science ®Google Scholar
• Yoo EM, Trinh KR, Tran D, Vasuthasawat A, Zhang J, Hoang B, Lichtenstein A, Morrison SL. Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma. J Interferon Cytokine Res 2015; 35:281-91; PMID:25353626; http://dx.doi.org/10.1089/jir.2014.0125
   PubMed Web of Science ®Google Scholar
• Xuan C, Steward KK, Timmerman JM, Morrison SL. Targeted delivery of interferon-α via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood 2010; 115:2864-71; PMID:20139095; http://dx.doi.org/10.1182/blood-2009-10-250555
   PubMed Web of Science ®Google Scholar
• Trinh KR, Vasuthasawat A, Steward KK, Yamada RE, Timmerman JM, Morrison SL. Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas. J Immunother 2013; 36:305-18; PMID:23719241; http://dx.doi.org/10.1097/CJI.0b013e3182993eb9
   PubMed Web of Science ®Google Scholar
• Huang TH, Chintalacharuvu KR, Morrison SL. Targeting IFN-α to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities. J Immunol 2007; 179:6881-8; PMID:17982079; http://dx.doi.org/10.4049/jimmunol.179.10.6881
   PubMed Web of Science ®Google Scholar
• Wijdenes J, Vooijs WC, Clement C, Post J, Morard F, Vita N, Laurent P, Sun RX, Klein B, Dore JM. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 1996; 94:318-23; PMID:8759892; http://dx.doi.org/10.1046/j.1365-2141.1996.d01-1811.x
   PubMed Web of Science ®Google Scholar
• Romano A, Conticello C, Di Raimondo F. Bortezomib for the treatment of previously untreated multiple myeloma. Immunotherapy 2013; 5:327-52; PMID:23557417; http://dx.doi.org/10.2217/imt.13.14
   PubMed Web of Science ®Google Scholar
• Lesinski GB, Raig ET, Guenterberg K, Brown L, Go MR, Shah NN, Lewis A, Quimper M, Hade E, Young G, et al. IFN-α and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis. Cancer Res 2008; 68:8351-60; PMID:18922907; http://dx.doi.org/10.1158/0008-5472.CAN-08-0426
   PubMed Web of Science ®Google Scholar
• Papageorgiou A, Kamat A, Benedict WF, Dinney C, McConkey DJ. Combination therapy with IFN-α plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther 2006; 5:3032-41; PMID:17172406; http://dx.doi.org/10.1158/1535-7163.MCT-05-0474
   PubMed Web of Science ®Google Scholar
• Lavoie TB, Kalie E, Crisafulli-Cabatu S, Abramovich R, DiGioia G, Moolchan K, Pestka S, Schreiber G. Binding and activity of all human α interferon subtypes. Cytokine 2011; 56:282-9; PMID:21856167; http://dx.doi.org/10.1016/j.cyto.2011.07.019
   PubMed Web of Science ®Google Scholar
• Kalie E, Jaitin DA, Abramovich R, Schreiber G. An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities. J Biol Chem 2007; 282:11602-11; PMID:17310065; http://dx.doi.org/10.1074/jbc.M610115200
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 1981; 115:207-16; PMID:7227366; http://dx.doi.org/10.1111/j.1432-1033.1981.tb06218.x
   PubMedGoogle Scholar
• Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol 2014; 14:36-49; PMID:24362405; http://dx.doi.org/10.1038/nri3581
   PubMed Web of Science ®Google Scholar
• Arulampalam V, Kolosenko I, Hjortsberg L, Bjorklund AC, Grander D, Tamm KP. Activation of STAT1 is required for interferon-α-mediated cell death. Exp Cell Res 2011; 317:9-19; PMID:20937272; http://dx.doi.org/10.1016/j.yexcr.2010.10.002
   PubMed Web of Science ®Google Scholar
• Shaffer AL, Emre NT, Romesser PB, Staudt LM. IRF4: Immunity. Malignancy! Therapy? Clin Cancer Res 2009; 15:2954-61; PMID:19383829; http://dx.doi.org/10.1158/1078-0432.CCR-08-1845
   PubMed Web of Science ®Google Scholar
• Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, Powell J, Dave S, Yu X, Zhao H, et al. IRF4 addiction in multiple myeloma. Nature 2008; 454:226-31; PMID:18568025; http://dx.doi.org/10.1038/nature07064
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Green DR. Do inducers of apoptosis trigger caspase-independent cell death? Nat Rev Mol Cell Biol 2005; 6:268-75; PMID:15714200; http://dx.doi.org/10.1038/nrm1573
   PubMed Web of Science ®Google Scholar
• Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009; 114:1046-52; PMID:19436050; http://dx.doi.org/10.1182/blood-2009-01-199604
   PubMed Web of Science ®Google Scholar
• Cregan SP, Dawson VL, Slack RS. Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene 2004; 23:2785-96; PMID:15077142; http://dx.doi.org/10.1038/sj.onc.1207517
   PubMed Web of Science ®Google Scholar
• Peleg-Shulman T, Tsubery H, Mironchik M, Fridkin M, Schreiber G, Shechter Y. Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period. J Med Chem 2004; 47:4897-904; PMID:15369394; http://dx.doi.org/10.1021/jm0497693
   PubMed Web of Science ®Google Scholar
• Borden EC. Review: Milstein Award lecture: interferons and cancer: where from here? J Interferon Cytokine Res 2005; 25:511-27; PMID:16181052; http://dx.doi.org/10.1089/jir.2005.25.511
   PubMed Web of Science ®Google Scholar
• Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007; 6:975-90; PMID:18049472; http://dx.doi.org/10.1038/nrd2422
   PubMed Web of Science ®Google Scholar
• Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000; 191:1777-88; PMID:10811870; http://dx.doi.org/10.1084/jem.191.10.1777
   PubMed Web of Science ®Google Scholar
• Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today 1996; 17:369-72; PMID:8783497; http://dx.doi.org/10.1016/0167-5699(96)10027-X
   PubMedGoogle Scholar
• Verfaillie T, Salazar M, Velasco G, Agostinis P. Linking ER stress to autophagy: potential implications for cancer therapy. Int J Cell Biol 2010; 2010:930509; PMID:20145727; http://dx.doi.org/10.1155/2010/930509
   PubMedGoogle Scholar
• Santos CX, Tanaka LY, Wosniak J, Laurindo FR. Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. Antioxid Redox Signal 2009; 11:2409-27; PMID:19388824; http://dx.doi.org/10.1089/ars.2009.2625
   PubMed Web of Science ®Google Scholar
• Kim HS, Lee MS. Essential role of STAT1 in caspase-independent cell death of activated macrophages through the p38 mitogen-activated protein kinase/STAT1/reactive oxygen species pathway. Mol Cell Biol 2005; 25:6821-33; PMID:16024814; http://dx.doi.org/10.1128/MCB.25.15.6821-6833.2005
   PubMed Web of Science ®Google Scholar
• Markowitz J, Luedke EA, Grignol VP, Hade EM, Paul BK, Mundy-Bosse BL, Brooks TR, Dao TV, Kondalasula SV, Lesinski GB, et al. A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma. J Immunother 2014; 37:55-62; PMID:24316557; http://dx.doi.org/10.1097/CJI.0000000000000009
   PubMed Web of Science ®Google Scholar
• Huang X, Di Liberto M, Jayabalan D, Liang J, Ely S, Bretz J, Shaffer AL, Louie T, Chen I, Randolph S, et al. Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood 2012; 120:1095-106; PMID:22718837; http://dx.doi.org/10.1182/blood-2012-03-415984
   PubMed Web of Science ®Google Scholar
• Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J, Einhorn S, Grander D. Mechanisms of interferon-α induced apoptosis in malignant cells. Oncogene 2002; 21:1251-62; PMID:11850845; http://dx.doi.org/10.1038/sj.onc.1205179
   PubMed Web of Science ®Google Scholar
• Gu H, Chen X, Gao G, Dong H. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells. Mol Cancer Ther 2008; 7:2298-307; PMID:18723477; http://dx.doi.org/10.1158/1535-7163.MCT-08-0186
   PubMed Web of Science ®Google Scholar
• Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003; 8:237-49; PMID:12766484; http://dx.doi.org/10.1023/A:1023668705040
   PubMed Web of Science ®Google Scholar
• Dong H, Chen L, Chen X, Gu H, Gao G, Gao Y, Dong B. Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells. Leuk Lymphoma 2009; 50:974-84; PMID:19391038; http://dx.doi.org/10.1080/10428190902895780
   PubMed Web of Science ®Google Scholar
• Yanase N, Ohshima K, Ikegami H, Mizuguchi J. Cytochrome c release, mitochondrial membrane depolarization, caspase-3 activation, and Bax-α cleavage during IFN-α-induced apoptosis in Daudi B lymphoma cells. J Interferon Cytokine Res 2000; 20:1121-9; PMID:11152579; http://dx.doi.org/10.1089/107999000750053799
   PubMed Web of Science ®Google Scholar
• Bonvini P, Zorzi E, Basso G, Rosolen A. Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD30+ anaplastic large cell lymphoma. Leukemia 2007; 21:838-42; PMID:17268529; http://dx.doi.org/10.1038/sj.leu.2404528
   PubMed Web of Science ®Google Scholar
• Quesada P, Malanga M, Di Meglio S, De Lorenzo S, Fabbrocini A, Garbi C, Bianco AR, Pepe S. Recombinant IFN-alpha2b treatment activates poly (ADPR) polymerase-1 (PARP-1) in KB cancer cells. Eur J Cancer 2003; 39:2103-9; PMID:12957467; http://dx.doi.org/10.1016/S0959-8049(03)00433-7
   PubMed Web of Science ®Google Scholar
• Ly JD, Grubb D, Lawen A. The mitochondrial membrane potential (delta psi m) in apoptosis; an update. Apoptosis 2003; 8:115-28; PMID:12766472; http://dx.doi.org/10.1023/A:1022945107762
   PubMed Web of Science ®Google Scholar